Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bladder Cancer, General Internal Medicine, Kidney Cancer, Urological Oncology
Education and Experience
Training
- University of Southern California Keck School of Medicine (Los Angeles CA)/ (2004)
Residencies
- University of Southern California Medical Center (Los Angeles CA)/ Internal Medicine (2007)
Fellowships
- Cleveland Clinic (Cleveland OH)/ Hematology/Oncology (2010)
Certifications
- Medical Oncology, American Board of Internal Medicine (2010)
- Internal Medicine, American Board of Internal Medicine (2007)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-614-0682
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Dr. Kims research is focused on translational research projects and clinical trials in renal cell cancer. Her research aims encompass discovering predictive as well as prognostic blood and tissue based biomarkers which can be applied in the clinical management of renal cell cancer patients. Dr. Kim also leads the renal cell cancer program development at Johns Hopkins. She completed her medical training and residency at University of Southern California and hematology and medical oncology fellowship at The Cleveland Clinic. She is board certified in internal medicine and medical oncology and has a growing clinic for patients with kidney cancer and bladder cancer.
Expertise
- Bladder Cancer
- General Internal Medicine
- Kidney Cancer
- Urological Oncology
Research
Research and Publications
1. George S, Pili R, Carducci MA, Kim JJ. The Role of Immunotherapy in Advanced Renal Cell Carcinoma. Submitted to JNCCN
2. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi, R. Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated With Sunitinib. Published online Aug 2011. Cancer
3. Kim JJ, Keizman D, Denmeade SR, Antonarakis ES. The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin. Invest. 2011 1(11), 1533-1544
4. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, et al. "Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Papillary Cell Renal Cell Carcinomas. American Journal of Surgical Pathology. Accepted.
5. Schultz L, Chaux A, Albadine R, Hicks, J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, Netto GJ. Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas. Am. J. Surg. Pathology 2011; 35(10):1549-56.
6. Keijman D. Huang P. Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinioma: A retrospective examination. Eur J Cancer 2011 May18 [Epub ahead of print]
7. Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, WalczakJ, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate. 2011 Mar 22 [Epub ahead of print].
8. Kim JJ, Redman B. Chapter 15. Kidney Cancer: Tumor Board Review Guideline and Case Reviews in Oncology. Demos Medical 2011
9. SA Vaziri, Kim JJ, MK Ganapathi, R Ganapathi. VEGF Polymorphisms: role in Response and Toxicity of TKIs. Current Oncology Reports. 2010; 12(2): 102-108
10. Kim JJ, Rini BI, Hansel DE. Von Hippel Lindau Syndrome. Adv. Exp. Med. Biol. 2010;685:228-49.
11. Kim JJ, BI Rini. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy. 2009; 6(3): 309-320
12. Hangai M. Kitaya N. Xu J. Chan CK. Kim JJ. Werb Z. Ryan SJ. Brooks PC. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology. 2002; 161(4):1429-37
13. Xu J. Rodriguez D. Petitclerc E. Kim JJ. Hangai M. Moon YS. Davis GE. Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology. 2001; 154(5):1069-79
2. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi, R. Association of VEGF and VEGFR2 Single Nucleotide Polymorphisms with Hypertension and Clinical Outcome in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated With Sunitinib. Published online Aug 2011. Cancer
3. Kim JJ, Keizman D, Denmeade SR, Antonarakis ES. The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin. Invest. 2011 1(11), 1533-1544
4. Chaux A, Schultz L, Albadine R, Hicks J, Kim JJ, Allaf ME, et al. "Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Papillary Cell Renal Cell Carcinomas. American Journal of Surgical Pathology. Accepted.
5. Schultz L, Chaux A, Albadine R, Hicks, J, Kim JJ, De Marzo AM, Allaf ME, Carducci MA, Rodriguez R, Hammers H, Argani P, Reuter VE, Netto GJ. Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas. Am. J. Surg. Pathology 2011; 35(10):1549-56.
6. Keijman D. Huang P. Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinioma: A retrospective examination. Eur J Cancer 2011 May18 [Epub ahead of print]
7. Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, WalczakJ, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate. 2011 Mar 22 [Epub ahead of print].
8. Kim JJ, Redman B. Chapter 15. Kidney Cancer: Tumor Board Review Guideline and Case Reviews in Oncology. Demos Medical 2011
9. SA Vaziri, Kim JJ, MK Ganapathi, R Ganapathi. VEGF Polymorphisms: role in Response and Toxicity of TKIs. Current Oncology Reports. 2010; 12(2): 102-108
10. Kim JJ, Rini BI, Hansel DE. Von Hippel Lindau Syndrome. Adv. Exp. Med. Biol. 2010;685:228-49.
11. Kim JJ, BI Rini. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma. Therapy. 2009; 6(3): 309-320
12. Hangai M. Kitaya N. Xu J. Chan CK. Kim JJ. Werb Z. Ryan SJ. Brooks PC. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology. 2002; 161(4):1429-37
13. Xu J. Rodriguez D. Petitclerc E. Kim JJ. Hangai M. Moon YS. Davis GE. Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology. 2001; 154(5):1069-79
Research Interests
- prostate cancer
- bladder cancer
- kidney cancer
- testicular cancer
- urothelial cancers
- genetic polymorphisms
More Info
Languages
- English
- Korean
Clinical Trials
- kidney cancer
- urothelial cancers
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts